

# Todd M Morgan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2940833/publications.pdf>

Version: 2024-02-01

229  
papers

8,445  
citations

41344

49  
h-index

64796

79  
g-index

234  
all docs

234  
docs citations

234  
times ranked

10917  
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of a Whole-urine, Multiplexed, Next-generation RNA-sequencing Assay for Early Detection of Aggressive Prostate Cancer. <i>European Urology Oncology</i> , 2022, 5, 430-439.	5.4	8
2	Active surveillance for prostate cancer: selection criteria, guidelines, and outcomes. <i>World Journal of Urology</i> , 2022, 40, 35-42.	2.2	13
3	Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 677-683.	3.9	15
4	Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. <i>Cancer</i> , 2022, 128, 269-274.	4.1	3
5	Association of MyProstateScore (MPS) with prostate cancer grade in the radical prostatectomy specimen. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 4.e1-4.e7.	1.6	2
6	Genetic factors associated with prostate cancer conversion from active surveillance to treatment. <i>Human Genetics and Genomics Advances</i> , 2022, 3, 100070.	1.7	10
7	Molecular Characterization of Clear Cell Renal Cell Carcinoma Reveals Prognostic Significance of Epithelial-mesenchymal Transition Gene Expression Signature. <i>European Urology Oncology</i> , 2022, 5, 92-99.	5.4	5
8	Active Surveillance: Very Much "Preferred" for Low-Risk Prostate Cancer. <i>Journal of Urology</i> , 2022, 207, 262-264.	0.4	3
9	A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. <i>European Urology</i> , 2022, 81, 576-585.	1.9	21
10	Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort. <i>Journal of Urology</i> , 2022, 207, 805-813.	0.4	3
11	Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. <i>European Urology Open Science</i> , 2022, 35, 59-67.	0.4	13
12	Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naïve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). <i>International Journal of Molecular Sciences</i> , 2022, 23, 4.	4.1	6
13	Urinary MyProstateScore (MPS) to Rule out Clinically-Significant Cancer in Men with Equivocal (PI-RADS 3) Multiparametric MRI: Addressing an Unmet Clinical Need. <i>Urology</i> , 2022, 164, 184-190.	1.0	8
14	Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance. <i>Cancer Medicine</i> , 2022, , .	2.8	3
15	Prostate Cancer With Peritoneal Carcinomatosis: A Robotic-assisted Radical Prostatectomy-based Case Series. <i>Urology</i> , 2022, 167, 171-178.	1.0	4
16	Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancer. <i>BMC Cancer</i> , 2022, 22, 494.	2.6	8
17	Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. <i>Npj Digital Medicine</i> , 2022, 5, .	10.9	34
18	Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative. <i>European Urology Open Science</i> , 2022, 41, 126-133.	0.4	5

#	ARTICLE	IF	CITATIONS
19	Radical prostatectomy for patients with high-risk, very-high risk, or radiographic suspicion for metastatic prostate cancer: Perioperative and early oncologic results from the MUSIC statewide collaborative. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 380.e1-380.e9.	1.6	0
20	Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis. <i>BJU International</i> , 2021, 128, 79-87.	2.5	10
21	Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance. <i>BJU International</i> , 2021, 127, 96-107.	2.5	15
22	Serial Molecular Profiling of Low-grade Prostate Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study. <i>European Urology</i> , 2021, 79, 456-465.	1.9	8
23	NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 174-185.	0.8	77
24	Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. <i>BJU International</i> , 2021, 127, 528-537.	2.5	10
25	A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. <i>European Urology</i> , 2021, 79, 374-383.	1.9	93
26	Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2021, 39, 136-144.	1.6	52
27	Multigene model for predicting metastatic prostate cancer using circulating tumor cells by microfluidic magnetophoresis. <i>Cancer Science</i> , 2021, 112, 859-870.	3.9	11
28	De novo neuroendocrine transdifferentiation in primary prostate cancer—a phenotype associated with advanced clinico-pathologic features and aggressive outcome. <i>Medical Oncology</i> , 2021, 38, 26.	2.5	18
29	Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. <i>Lancet Oncology</i> , The, 2021, 22, 402-410.	10.7	79
30	Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach. <i>Journal of Urology</i> , 2021, 205, 732-739.	0.4	21
31	Understanding the Barriers to Neoadjuvant Chemotherapy in Patients with Muscle Invasive Bladder Cancer: A Quality Improvement Initiative. <i>Urology Practice</i> , 2021, 8, 217-225.	0.5	1
32	Antisense oligonucleotides and nucleic acids generate hypersensitive platelets. <i>Thrombosis Research</i> , 2021, 200, 64-71.	1.7	11
33	Delayed Urological Cancer Care during the COVID-19 Pandemic: Urologists'™ Experience. <i>Urology Practice</i> , 2021, 8, 367-372.	0.5	3
34	Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	136
35	PCN166 Comparative Effectiveness and Cost-Effectiveness of Reflex Testing Men with Intermediate PSA Levels: A Systematic Model-Based Analysis. <i>Value in Health</i> , 2021, 24, S50.	0.3	0
36	Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer. <i>European Urology</i> , 2021, 80, 71-81.	1.9	35

#	ARTICLE	IF	CITATIONS
37	Biomarkers for detection of clinically significant prostate cancer: contemporary clinical data and future directions. <i>Translational Andrology and Urology</i> , 2021, 10, 3091-3103.	1.4	23
38	Association of Urinary MyProstateScore, Age, and Prostate Volume in a Longitudinal Cohort of Healthy Men: Long-term Findings from the Olmsted County Study. <i>European Urology Open Science</i> , 2021, 29, 30-35.	0.4	2
39	Initial Findings from a High Genetic Risk Prostate Cancer Clinic. <i>Urology</i> , 2021, 156, 96-103.	1.0	5
40	Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort. <i>Journal of Urology</i> , 2021, 206, 1147-1156.	0.4	14
41	Reply by Authors. <i>Journal of Urology</i> , 2021, 206, 1156.	0.4	0
42	Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 4345-4354.	2.2	4
43	Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States. <i>Value in Health</i> , 2021, 24, 1111-1117.	0.3	9
44	Genetically Informed Prostate Cancer Screening. <i>Urologic Clinics of North America</i> , 2021, 48, 373-386.	1.8	1
45	Effect of Diagnostic Biopsy Practice Location on Grade/Volume Reclassification in Active Surveillance for Prostate Cancer: A Multicenter Analysis from the Canary PASS Cohort. <i>Urology Practice</i> , 2021, 8, 576-582.	0.5	1
46	Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC). <i>Biomedicines</i> , 2021, 9, 1247.	3.2	22
47	The European Urology Commitment to Gender Equity and Diversity: Expanding Cognitive Diversity through Inclusivity at the Podium. <i>European Urology</i> , 2021, 80, 450-453.	1.9	11
48	Prostate cancer clinical trial completion: The role of geography. <i>Contemporary Clinical Trials</i> , 2021, 111, 106600.	1.8	3
49	Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men. <i>JAMA Network Open</i> , 2021, 4, e2139769.	5.9	16
50	Overdiagnosis and Lives Saved by Reflex Testing Men With Intermediate Prostate-Specific Antigen Levels. <i>Journal of the National Cancer Institute</i> , 2020, 112, 384-390.	6.3	10
51	Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative. <i>European Urology Oncology</i> , 2020, 3, 80-91.	5.4	24
52	The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 3.e17-3.e27.	1.6	29
53	Pelvic lymph node dissection at robot-assisted radical prostatectomy: Assessing utilization and nodal metastases within a statewide quality improvement consortium. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 198-203.	1.6	5
54	Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 1474-1494.	1.6	141

#	ARTICLE	IF	CITATIONS
55	Correlation between cribriform/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22-gene genomic classifier. <i>Prostate</i> , 2020, 80, 146-152.	2.3	21
56	Should all prostate needle biopsy Gleason score 4+4=8 prostate cancers be high risk? Implications for shared decision-making and patient counselling. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 78.e1-78.e6.	1.6	6
57	Clinicopathological characterisation of renal cell carcinoma in young adults: a contemporary update and review of literature. <i>Histopathology</i> , 2020, 76, 875-887.	2.9	7
58	The Feasibility and Impact of a Presurgical Exercise Intervention Program (Prehabilitation) for Patients Undergoing Cystectomy for Bladder Cancer. <i>Urology</i> , 2020, 145, 106-112.	1.0	23
59	The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future. <i>European Urology</i> , 2020, 78, 731-742.	1.9	39
60	Impact of the MyProstateScore (MPS) Test on the Clinical Decision to Undergo Prostate Biopsy: Results From a Contemporary Academic Practice. <i>Urology</i> , 2020, 145, 204-210.	1.0	3
61	Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. <i>JCO Precision Oncology</i> , 2020, 4, 1228-1238.	3.0	2
62	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. <i>JAMA Oncology</i> , 2020, 6, 1912.	7.1	49
63	The DNA methylation landscape of advanced prostate cancer. <i>Nature Genetics</i> , 2020, 52, 778-789.	21.4	198
64	Comparison of biopsy under-sampling and annual progression using hidden markov models to learn from prostate cancer active surveillance studies. <i>Cancer Medicine</i> , 2020, 9, 9611-9619.	2.8	6
65	Development and Validation of a Deep-learning Model to Assist With Renal Cell Carcinoma Histopathologic Interpretation. <i>Urology</i> , 2020, 144, 152-157.	1.0	32
66	Rethinking the one-size-fits-most approach to venous thromboembolism prophylaxis after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 797.e1-797.e6.	1.6	3
67	Biopsy Cell Cycle Proliferation Score Predicts Adverse Surgical Pathology in Localized Renal Cell Carcinoma. <i>European Urology</i> , 2020, 78, 657-660.	1.9	10
68	Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. <i>JAMA Oncology</i> , 2020, 6, e203187.	7.1	30
69	Evaluating the Evidence to Support Clinical Use of the 22-Gene Genomic Classifier (Decipher) in Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, e902-e903.	0.8	0
70	Clinical implications of genomic evaluations for prostate cancer risk stratification, screening, and treatment: a narrative review. <i>Prostate International</i> , 2020, 8, 99-106.	2.3	16
71	Adrenergic Blockade Promotes Maintenance of Dormancy in Prostate Cancer Through Upregulation of GAS6. <i>Translational Oncology</i> , 2020, 13, 100781.	3.7	15
72	Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. <i>Journal of Clinical Oncology</i> , 2020, 38, 3024-3031.	1.6	26

#	ARTICLE	IF	CITATIONS
73	Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. <i>European Urology</i> , 2020, 78, 29-42.	1.9	110
74	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. <i>Journal of Clinical Oncology</i> , 2020, 38, 2798-2811.	1.6	170
75	Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. <i>JAMA Oncology</i> , 2020, 6, 735.	7.1	58
76	Wnt Signaling Drives Prostate Cancer Bone Metastatic Tropism and Invasion. <i>Translational Oncology</i> , 2020, 13, 100747.	3.7	36
77	17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. <i>Journal of Clinical Oncology</i> , 2020, 38, 1549-1557.	1.6	48
78	Pathologically Node-Positive Prostate Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2020, 26, 58-63.	2.0	1
79	Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 639.e1-639.e9.	1.6	15
80	Considerations in the Triage of Urologic Surgeries During the COVID-19 Pandemic. <i>European Urology</i> , 2020, 77, 663-666.	1.9	239
81	Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 646-653.	3.9	17
82	African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study. <i>Journal of Urology</i> , 2020, 203, 727-733.	0.4	30
83	PD62-09â€¦EVALUATING THE OUTCOMES OF ACTIVE SURVEILLANCE IN GLEASON GRADE GROUP 2 PROSTATE CANCER. <i>Journal of Urology</i> , 2020, 203, e1289.	0.4	1
84	Magnetic Resonance Imaging for the Detection of High Grade Cancer in the Canary Prostate Active Surveillance Study. <i>Journal of Urology</i> , 2020, 204, 701-706.	0.4	19
85	Clinical and morphologic review of 60 hereditary renal tumors from 30 hereditary renal cell carcinoma syndrome patients: lessons from a contemporary single institution series. <i>Medical Oncology</i> , 2019, 36, 74.	2.5	15
86	Circulating Tumor Cellâ€“Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer. <i>Neoplasia</i> , 2019, 21, 802-809.	5.3	32
87	Detection and isolation of disseminated tumor cells in bone marrow of patients with clinically localized prostate cancer. <i>Prostate</i> , 2019, 79, 1715-1727.	2.3	18
88	Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. <i>European Urology</i> , 2019, 76, 693-702.	1.9	18
89	Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell cycle risk score. <i>Personalized Medicine</i> , 2019, 16, 491-499.	1.5	9
90	Liquid biopsy: Where did it come from, what is it, and where is it going?. <i>Investigative and Clinical Urology</i> , 2019, 60, 139.	2.0	9

#	ARTICLE	IF	CITATIONS
91	EDITORIAL COMMENT. Urology, 2019, 126, 82.	1.0	0
92	Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). Prostate Cancer and Prostatic Diseases, 2019, 22, 438-445.	3.9	22
93	Individual and Population Comparisons of Surgery and Radiotherapy Outcomes in Prostate Cancer Using Bayesian Multistate Models. JAMA Network Open, 2019, 2, e187765.	5.9	17
94	Association of Black Race With Prostate Cancerâ€“Specific and Other-Cause Mortality. JAMA Oncology, 2019, 5, 975.	7.1	288
95	Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. International Journal of Radiation Oncology Biology Physics, 2019, 104, 778-789.	0.8	247
96	The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. European Urology, 2019, 76, 268-272.	1.9	28
97	Utilization of Salvage Radiation Therapy for Biochemical Recurrence After Radical Prostatectomy. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1030-1034.	0.8	20
98	Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a <i>de novo</i> low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer. Clinical Cancer Research, 2019, 25, 6721-6730.	7.0	74
99	Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. European Urology Oncology, 2019, 2, 333-336.	5.4	8
100	Tissue-based genomics. Current Opinion in Urology, 2019, 29, 598-604.	1.8	3
101	Biologic Significance of Magnetic Resonance Imaging Invisibility in Localized Prostate Cancer. JCO Precision Oncology, 2019, 3, 1-12.	3.0	9
102	Circulating Tumor Cells as a Predictor of Treatment Response in Clinically Localized Prostate Cancer. JCO Precision Oncology, 2019, 3, 1-9.	3.0	18
103	Optimizing Prostate Cancer Surveillance: Using Data-driven Models for Informed Decision-making. European Urology, 2019, 75, 918-919.	1.9	3
104	Detection of CTC Clusters and a Dedifferentiated RNAâ€“Expression Survival Signature in Prostate Cancer. Advanced Science, 2019, 6, 1801254.	11.2	30
105	Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. European Urology, 2019, 75, 523-531.	1.9	58
106	Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma. Human Pathology, 2019, 86, 76-84.	2.0	16
107	Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance. BJU International, 2019, 123, 846-853.	2.5	21
108	International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy. Journal of Urology, 2019, 201, 284-291.	0.4	18



#	ARTICLE	IF	CITATIONS
109	Multi-institutional Survival Analysis of Incidental Pathologic T3a Upstaging in Clinical T1 Renal Cell Carcinoma Following Partial Nephrectomy. <i>Urology</i> , 2018, 117, 95-100.	1.0	26
110	Prognostic importance of lymphovascular invasion in urothelial carcinoma of the renal pelvis. <i>Cancer</i> , 2018, 124, 2507-2514.	4.1	13
111	Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. <i>Molecular Cancer Research</i> , 2018, 16, 643-654.	3.4	33
112	CXCL12 <sup>hi</sup> Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes. <i>Cancer Research</i> , 2018, 78, 2026-2039.	0.9	46
113	Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. <i>European Urology</i> , 2018, 73, 706-712.	1.9	17
114	Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. <i>European Urology</i> , 2018, 74, 211-217.	1.9	30
115	Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival. <i>European Urology</i> , 2018, 74, 413-419.	1.9	29
116	The Fate of Radical Cystectomy Patients after Hospital Discharge: Understanding the Black Box of the Pre-readmission Interval. <i>European Urology Focus</i> , 2018, 4, 711-717.	3.1	13
117	Erectile function after stereotactic body radiotherapy for localized prostate cancer. <i>BJU International</i> , 2018, 121, 61-68.	2.5	24
118	A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. <i>European Urology</i> , 2018, 73, 156-165.	1.9	55
119	The prognostic effect of salvage surgery and radiotherapy in patients with recurrent primary urethral carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 10.e7-10.e14.	1.6	12
120	Estimating the Optimal Personalized Treatment Strategy Based on Selected Variables to Prolong Survival via Random Survival Forest with Weighted Bootstrap. <i>Journal of Biopharmaceutical Statistics</i> , 2018, 28, 362-381.	0.8	9
121	Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. <i>European Urology</i> , 2018, 74, 107-114.	1.9	54
122	A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma. <i>European Urology</i> , 2018, 73, 763-769.	1.9	63
123	Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?. <i>Journal of Clinical Oncology</i> , 2018, 36, 937-941.	1.6	7
124	Clinical Utility of Gene Expression Classifiers in Men With Newly Diagnosed Prostate Cancer. <i>JCO Precision Oncology</i> , 2018, 2, 1-15.	3.0	13
125	Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 3251-3258.	1.6	129
126	Staging the Host: Personalizing Risk Assessment for Radical Cystectomy Patients. <i>European Urology Oncology</i> , 2018, 1, 292-304.	5.4	54



#	ARTICLE	IF	CITATIONS
127	Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure. <i>European Urology Oncology</i> , 2018, 1, 276-282.	5.4	6
128	Association Between Early Confirmatory Testing and the Adoption of Active Surveillance for Men With Favorable-risk Prostate Cancer. <i>Urology</i> , 2018, 118, 127-133.	1.0	10
129	Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications. <i>European Urology</i> , 2018, 74, 741-753.	1.9	54
130	Tradeoffs in Refining the Diagnosis of Prostate Cancer. <i>European Urology</i> , 2018, 74, 729-730.	1.9	0
131	Comprehensive molecular profiling of multifocal prostate cancer challenges the robustness of prostate cancer prognostic signatures. <i>European Urology Supplements</i> , 2018, 17, e539.	0.1	0
132	Transcriptomic heterogeneity in multifocal prostate cancer. <i>JCI Insight</i> , 2018, 3, .	5.0	71
133	Oncologic outcomes in patients with nonurothelial bladder cancer. <i>Indian Journal of Urology</i> , 2018, 34, 39.	0.6	19
134	Adjuvant Radiation Therapy for High-Risk Post-prostatectomy Patients. , 2018, , 81-99.		0
135	Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma. <i>European Urology Focus</i> , 2017, 3, 502-509.	3.1	25
136	Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study. <i>BJU International</i> , 2017, 120, 351-357.	2.5	10
137	Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. <i>Cancer Discovery</i> , 2017, 7, 750-765.	9.4	112
138	Minimally Invasive Inguinal Lymphadenectomy in the Management of Penile Carcinoma. <i>Urology</i> , 2017, 106, 113-118.	1.0	26
139	Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. <i>European Urology</i> , 2017, 72, 448-454.	1.9	61
140	Understanding Treatment Disconnect and Mortality Trends in Renal Cell Carcinoma Using Tumor Registry Data. <i>Medical Care</i> , 2017, 55, 398-404.	2.4	36
141	Adjuvant Versus Early Salvage Radiation Therapy Following Radical Prostatectomy for Men with Localized Prostate Cancer. <i>Current Urology Reports</i> , 2017, 18, 55.	2.2	15
142	Two-Stage Biomarker Protocols for Improving the Precision of Early Detection of Prostate Cancer. <i>Medical Decision Making</i> , 2017, 37, 815-826.	2.4	12
143	Author Reply. <i>Urology</i> , 2017, 102, 99.	1.0	0
144	No Differences in Population-based Readmissions After Open and Robotic-assisted Radical Cystectomy: Implications for Post-discharge Care. <i>Urology</i> , 2017, 104, 77-83.	1.0	27

#	ARTICLE	IF	CITATIONS
145	Epidemiology of the Small Renal Mass and the Treatment Disconnect Phenomenon. <i>Urologic Clinics of North America</i> , 2017, 44, 147-154.	1.8	37
146	Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 985-991.	7.0	24
147	Potential Implications of Shortening Length of Stay Following Radical Cystectomy in a Pre-ERAS Population. <i>Urology</i> , 2017, 102, 92-99.	1.0	14
148	Rare Presentation of Metastatic Cystic Trophoblastic Tumor in a Patient Without Prior Chemotherapy. <i>Urology Case Reports</i> , 2017, 13, 154-157.	0.3	4
149	Diagnostic accuracy of the PROMIS study. <i>Lancet, The</i> , 2017, 390, 362.	13.7	1
150	Examining the Value of Video Visits to Patients in an Outpatient Urology Clinic. <i>Urology</i> , 2017, 110, 31-35.	1.0	26
151	HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone. <i>Cancer Research</i> , 2017, 77, 74-85.	0.9	137
152	Very Early Salvage Radiotherapy Improves Distant Metastasis-Free Survival. <i>Journal of Urology</i> , 2017, 197, 662-668.	0.4	76
153	Treatment of ureteral anastomotic strictures with reimplantation and survival after cystectomy and urinary diversion. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 33.e1-33.e9.	1.6	8
154	Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. <i>Oncotarget</i> , 2017, 8, 89848-89866.	1.8	45
155	Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2017, 13, 621-625.	2.5	40
156	Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone. <i>Journal of Clinical Investigation</i> , 2017, 128, 248-266.	8.2	103
157	Independent surgical validation of the new prostate cancer grade grouping system. <i>BJU International</i> , 2016, 118, 763-769.	2.5	48
158	Growth Arrest-Specific 6 (GAS6) Promotes Prostate Cancer Survival by G <sub>1</sub> Arrest/S Phase Delay and Inhibition of Apoptosis During Chemotherapy in Bone Marrow. <i>Journal of Cellular Biochemistry</i> , 2016, 117, 2815-2824.	2.6	23
159	NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 509-519.	4.9	268
160	Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 415.e1-415.e6.	1.6	18
161	Telemedicine in Urology: State of the Art. <i>Urology</i> , 2016, 94, 10-16.	1.0	74
162	Effect of delayed resection after initial surveillance and tumor growth rate on final surgical pathology in patients with small renal masses (SRMs). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 486.e9-486.e15.	1.6	12

#	ARTICLE	IF	CITATIONS
163	Oncological Outcomes of Patients with Concomitant Bladder and Urethral Carcinoma. <i>Urologia Internationalis</i> , 2016, 97, 134-141.	1.3	7
164	Predictors of Delayed Intervention for Patients on Active Surveillance for Small Renal Masses: Does Renal Mass Biopsy Influence Our Decision?. <i>Urology</i> , 2016, 98, 88-96.	1.0	22
165	A Multi-Center International Study Assessing the Impact of Differences in Baseline Characteristics and Perioperative Care Following Radical Cystectomy. <i>Bladder Cancer</i> , 2016, 2, 251-261.	0.4	13
166	The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 381-394.	0.4	15
167	Comparison of Percutaneous Renal Mass Biopsy and R.E.N.A.L. Nephrometry Score Nomograms for Determining Benign Vs Malignant Disease and Low-risk Vs High-risk Renal Tumors. <i>Urology</i> , 2016, 96, 87-92.	1.0	16
168	Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes. <i>European Urology Focus</i> , 2016, 2, 532-539.	3.1	23
169	Ureteral Involvement Within an Incarcerated Inguinal Hernia in a Patient With Crossed-fused Renal Ectopia. <i>Urology Case Reports</i> , 2016, 7, 20-22.	0.3	2
170	Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma. <i>World Journal of Urology</i> , 2016, 34, 97-103.	2.2	51
171	Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. <i>Neoplasia</i> , 2016, 18, 1-9.	5.3	25
172	Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence. <i>Journal of Urology</i> , 2016, 196, 405-411.	0.4	89
173	Age, Gender and R.E.N.A.L. Nephrometry Score do not Improve the Accuracy of a Risk Stratification Algorithm Based on Biopsy and Mass Size for Assigning Surveillance versus Treatment of Renal Tumors. <i>Journal of Urology</i> , 2016, 195, 574-580.	0.4	15
174	Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples. <i>PLoS ONE</i> , 2016, 11, e0147400.	2.5	82
175	Endogenous GAS6 and Mer receptor signaling regulate prostate cancer stem cells in bone marrow. <i>Oncotarget</i> , 2016, 7, 25698-25711.	1.8	30
176	Hypoalbuminaemia is associated with mortality in patients undergoing cytoreductive nephrectomy. <i>BJU International</i> , 2015, 116, 351-357.	2.5	29
177	Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy. <i>Cancer</i> , 2015, 121, 4071-4079.	4.1	28
178	Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy. <i>Cancer Research</i> , 2015, 75, 5219-5227.	0.9	94
179	Patient Psoas Muscle Mass as a Predictor of Complications and Survival After Radical Cystectomy. <i>Current Urology Reports</i> , 2015, 16, 79.	2.2	15
180	Platelet-Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling. <i>Neoplasia</i> , 2015, 17, 490-496.	5.3	8

#	ARTICLE	IF	CITATIONS
181	Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2015, 67, 241-249.	1.9	235
182	The Use of Social Media in Endourology: An Analysis of the 2013 World Congress of Endourology Meeting. <i>Journal of Endourology</i> , 2015, 29, 615-620.	2.1	31
183	Screening for Prostate Cancer—Beyond Total PSA, Utilization of Novel Biomarkers. <i>Current Urology Reports</i> , 2015, 16, 63.	2.2	4
184	Impact of a Genomic Classifier of Metastatic Risk on Postprostatectomy Treatment Recommendations by Radiation Oncologists and Urologists. <i>Urology</i> , 2015, 86, 35-40.	1.0	27
185	Transperineal Template Guided Prostate Biopsy Selects Candidates for Active Surveillance—How Many Cores are Enough?. <i>Journal of Urology</i> , 2015, 194, 674-679.	0.4	25
186	Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series. <i>Asian Journal of Urology</i> , 2015, 2, 53-58.	1.2	12
187	Molecular and Immunohistochemical Characterization Reveals Novel BRAF Mutations in Metanephric Adenoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 549-557.	3.7	43
188	Clinicopathologic characteristics of anterior prostate cancer (APC), including correlation with previous biopsy pathology. <i>Medical Oncology</i> , 2015, 32, 249.	2.5	10
189	Gleason 6 Prostate Cancer: Translating Biology into Population Health. <i>Journal of Urology</i> , 2015, 194, 626-634.	0.4	75
190	Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 21.e11-21.e17.	1.6	25
191	Targeting Efferocytic M2 Monocytes and Macrophages Offers Therapeutic Promise in Prostate Cancer Skeletal Metastasis. <i>FASEB Journal</i> , 2015, 29, LB457.	0.5	0
192	Engaging responsibly with social media: the <sc>BJU</sc> guidelines. <i>BJU International</i> , 2014, 114, 9-11.	2.5	74
193	Incidence and predictors of understaging in patients with clinical <sc>T</sc>1 urothelial carcinoma undergoing radical cystectomy. <i>BJU International</i> , 2014, 113, 894-899.	2.5	67
194	Editorial Comment. <i>Urology</i> , 2014, 84, 1432-1433.	1.0	0
195	Sharpening the focus on causes and timing of readmission after radical cystectomy for bladder cancer. <i>Cancer</i> , 2014, 120, 1409-1416.	4.1	65
196	Papillary renal cell carcinoma revisited: a comprehensive histomorphologic study with outcome correlations. <i>Human Pathology</i> , 2014, 45, 1139-1146.	2.0	25
197	HRAS mutations are frequent in inverted urothelial neoplasms. <i>Human Pathology</i> , 2014, 45, 1957-1965.	2.0	39
198	Reply. <i>Urology</i> , 2014, 84, 379.	1.0	0

#	ARTICLE	IF	CITATIONS
199	Understanding the Relationship Between Tumor Size, Gland Size, and Disease Aggressiveness in Men With Prostate Cancer. <i>Urology</i> , 2014, 84, 373-379.	1.0	14
200	European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media. <i>European Urology</i> , 2014, 66, 628-632.	1.9	72
201	Blood loss associated with radical cystectomy: A prospective, randomized study comparing Impact LigaSure vs. stapling device. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 45.e11-45.e15.	1.6	16
202	Prostate Cancer Early Detection, Version 1.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1211-1219.	4.9	76
203	Comparison of prostate cancer diagnosis in patients receiving unrelated urological and nonurological cancer care. <i>BJU International</i> , 2013, 112, 161-168.	2.5	5
204	Editorial Comment. <i>Journal of Urology</i> , 2013, 189, 460-461.	0.4	1
205	Imaging the Clear Cell Renal Cell Carcinoma Proteome. <i>Journal of Urology</i> , 2013, 189, 1097-1103.	0.4	40
206	Anatomic Basis for Lymph Node Counts as Measure of Lymph Node Dissection Extent: A Cadaveric Study. <i>Urology</i> , 2013, 81, 358-363.	1.0	43
207	Restaging Transurethral Resection for Non-Muscle Invasive Bladder Cancer. <i>Urologic Clinics of North America</i> , 2013, 40, 295-304.	1.8	5
208	The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 871-877.	1.6	86
209	ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinoma. <i>BJU International</i> , 2012, 110, E641-6.	2.5	47
210	Editorial Comment. <i>Journal of Urology</i> , 2012, 188, 2127-2128.	0.4	0
211	Volume Outcomes of Cystectomy—Is it the Surgeon or the Setting?. <i>Journal of Urology</i> , 2012, 188, 2139-2144.	0.4	57
212	Inferior Vena Cava Filter Strut Perforation Discovered During Right Robotic-assisted Laparoscopic Partial Nephrectomy. <i>Urology</i> , 2012, 79, e49-e50.	1.0	7
213	Lymph Node Yield at Radical Cystectomy Predicts Mortality in Node-negative and not Node-positive Patients. <i>Urology</i> , 2012, 80, 632-640.	1.0	44
214	Surgical and Chemotherapeutic Management of Regional Lymph Nodes in Bladder Cancer. <i>Journal of Urology</i> , 2012, 188, 1081-1088.	0.4	19
215	Urinary Collecting System Invasion Is a Predictor for Overall and Disease-specific Survival in Locally Invasive Renal Cell Carcinoma. <i>Urology</i> , 2011, 78, 99-104.	1.0	21
216	Predicting the Probability of 90-Day Survival of Elderly Patients With Bladder Cancer Treated With Radical Cystectomy. <i>Journal of Urology</i> , 2011, 186, 829-834.	0.4	97

#	ARTICLE	IF	CITATIONS
217	Bladder cancer. <i>Current Opinion in Oncology</i> , 2011, 23, 275-282.	2.4	40
218	Preoperative Nutritional Status Is an Important Predictor of Survival in Patients Undergoing Surgery for Renal Cell Carcinoma. <i>European Urology</i> , 2011, 59, 923-928.	1.9	146
219	Bladder cancer. <i>Current Opinion in Oncology</i> , 2010, 22, 242-249.	2.4	32
220	Disseminated Tumor Cells in Prostate Cancer Patients after Radical Prostatectomy and without Evidence of Disease Predicts Biochemical Recurrence. <i>Clinical Cancer Research</i> , 2009, 15, 677-683.	7.0	218
221	Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway. <i>Current Cancer Drug Targets</i> , 2009, 9, 237-249.	1.6	244
222	RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. <i>Prostate</i> , 2008, 68, 861-871.	2.3	64
223	Primary Scrotal Cancer: Disease Characteristics and Increasing Incidence. <i>Urology</i> , 2008, 72, 1139-1143.	1.0	50
224	Genomic Alterations Indicate Tumor Origin and Varied Metastatic Potential of Disseminated Cells from Prostate Cancer Patients. <i>Cancer Research</i> , 2008, 68, 5599-5608.	0.9	50
225	Complications of Scrotal Surgery for Benign Conditions. <i>Urology</i> , 2007, 69, 616-619.	1.0	57
226	Hairpin-bisulfite PCR: Assessing epigenetic methylation patterns on complementary strands of individual DNA molecules. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 204-209.	7.1	203
227	Thymic stromal organization is regulated by the specificity of T cell receptor/major histocompatibility complex interactions. <i>European Journal of Immunology</i> , 1997, 27, 136-146.	2.9	25
228	Better Understanding the Timing of Androgen Deprivation (TOAD) Trial Outcomes: Impacts of Prior ADT. <i>JNCI Cancer Spectrum</i> , 0, , .	2.9	0
229	Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance. <i>Journal of Urology</i> , 0, , .	0.4	1